NFE2L2 and cancer: Importantly, it is well-recognized that sustained NRF2 signaling in cancer cells can be instrumental to the orchestration of a pro-oncogenic “program” that ultimately promotes the malignant progression and the development of therapy resistance, leading to poor clinical outcomes.